Vertex Pharmaceuticals (VRTX) total liabilities
Vertex Pharmaceuticals (VRTX) had total liabilities of $6.98B at the end of fiscal 2025 (December 31, 2025). That is 13.9% higher than the $6.12B of fiscal 2024. Figures as of 18 Nov 2026, 19:48 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Total liabilities, fiscal 2025
- $6.98B
- Change on fiscal 2024
- +13.9%
- Growth, 5 years
- +17.9% a year
- Growth, 10 years
- +17.4% a year
- Highest on record
- $6.98Bfiscal 2025
- Lowest on record
- $859.14Mfiscal 2009
- Fiscal years on record
- 172009–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Vertex Pharmaceuticals total liabilities, in more detail
Over the five fiscal years to 2025 total liabilities grew at a compound 17.9% a year; over ten years the rate was 17.4% a year. Across the 17 fiscal years on record (2009–2025), the highest was $6.98B in fiscal 2025 and the lowest $859.14M in fiscal 2009.
Total liabilities by fiscal year
Vertex Pharmaceuticals total liabilities, year by year
| Fiscal year | Total liabilities | Change | Year ended |
|---|---|---|---|
| 2025 | $6.98B | 13.9% up | |
| 2024 | $6.12B | 18.9% up | |
| 2023 | $5.15B | 21.5% up | |
| 2022 | $4.24B | 27.2% up | |
| 2021 | $3.33B | 8.7% up | |
| 2020 | $3.07B | 37.2% up | |
| 2019 | $2.23B | 23.3% up | |
| 2018 | $1.81B | 20.4% up | |
| 2017 | $1.50B | 3.5% down | |
| 2016 | $1.56B | 10.9% up | |
| 2015 | $1.40B | 13.4% up | |
| 2014 | $1.24B | 28.7% up | |
| 2013 | $962.64M | 36.9% down | |
| 2012 | $1.52B | 23.1% up | |
| 2011 | $1.24B | 1.4% up | |
| 2010 | $1.22B | 42.2% up | |
| 2009 | $859.14M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.
How to read it
It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.
Total liabilities at health care companies of similar size
| Company | Total liabilities | Fiscal year |
|---|---|---|
| Pfizer PFE | $121.39B | 2025 |
| Danaher DHR | $30.92B | 2025 |
| Intuitive Surgical ISRG | $2.52B | 2025 |
| Vertex Pharmaceuticals VRTX | $6.98B | 2025 |
| Medtronic MDT | $42.96B | 2026 |
| Bristol-Myers Squibb BMY | $71.53B | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Vertex Pharmaceuticals, figure by figure
- Vertex Pharmaceuticals market cap
- Vertex Pharmaceuticals revenue
- Vertex Pharmaceuticals earnings
- Vertex Pharmaceuticals earnings per share (EPS)
- Vertex Pharmaceuticals P/E ratio
- Vertex Pharmaceuticals P/S ratio
- Vertex Pharmaceuticals P/B ratio
- Vertex Pharmaceuticals free cash flow
- Vertex Pharmaceuticals operating margin
- Vertex Pharmaceuticals dividend
- Vertex Pharmaceuticals shares outstanding
- Vertex Pharmaceuticals total debt
- Vertex Pharmaceuticals cash on hand
- Vertex Pharmaceuticals total assets
- Vertex Pharmaceuticals net assets (shareholders' equity)
- Vertex Pharmaceuticals return on equity (ROE)
- Vertex Pharmaceuticals return on invested capital (ROIC)
Vertex Pharmaceuticals (VRTX) overview: price, valuation and scorecardAll health care companies by market value
Vertex Pharmaceuticals total liabilities: questions and answers
How large are Vertex Pharmaceuticals's total liabilities?
Vertex Pharmaceuticals (VRTX) had total liabilities of $6.98B at the end of fiscal 2025 (December 31, 2025). That is 13.9% higher than the $6.12B of fiscal 2024.
What is the growth rate of Vertex Pharmaceuticals's total liabilities?
Over the five fiscal years to 2025 total liabilities grew at a compound 17.9% a year; over ten years the rate was 17.4% a year.
What are the highest and lowest total liabilities figures on record for Vertex Pharmaceuticals?
Across the 17 fiscal years on record (2009–2025), the highest was $6.98B in fiscal 2025 and the lowest $859.14M in fiscal 2009.
How is Vertex Pharmaceuticals's total liabilities calculated?
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Vertex Pharmaceuticals it is on record here for 17 fiscal years, 2009 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: total liabilities
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Vertex Pharmaceuticals (VRTX) total liabilities”, data as of 18 November 2026. https://funkfolio.com/stock/VRTX/total-liabilities
Underlying data: the company's filings with the SEC and Yahoo Finance.